Results 211 to 220 of about 265,747 (298)
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang +8 more
wiley +1 more source
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy +16 more
wiley +1 more source
ABSTRACT Piezocatalytic therapy (PCT) harnesses mechanical energy to generate tumor‐lethal reactive oxygen species (ROS), but its efficacy is limited by rapid electron‐hole recombination and poor intratumoral retention. To overcome these limitations, we engineered heterostructured BiOCl@CuO nanosheets embedded in an injectable, conductive ...
Can Tian +7 more
wiley +1 more source
A neutrophil‐membrane‐camouflaged nanoplatform (RC@NMVs) exploits tumor inflammation to target and accumulate in tumors. Intracellular Ca2+ overload is triggered via lysosomal CaP dissolution and Ru red‐mediated Ca2+ channel blockade, synergistically inducing gasdermin‐mediated pyroptosis.
Yingying Liu +8 more
wiley +1 more source
This study utilizes programmable mechanical pressure as a therapeutic enhancer to establish a mechano‐chemotherapy strategy. Controlled pressure activates the mechanosensitive ion channel Piezo1 in bladder cancer, triggering a calcium ion cascade that transiently and reversibly amplifies membrane permeability to chemotherapeutics.
Minghai Ma +16 more
wiley +1 more source
An implantable hydrogel is designed to hold gene transfection agents engineered to turn early recurrent tumor cells into generators of synthetic EVs. These synthetic EVs can express engineered miR‐26a (E‐miR‐26a) for highly sensitive detection and PD‐1 (a PD‐L1‐blocking agent) for therapeutic intervention, thereby enabling early detection and ...
Junli Zhang +7 more
wiley +1 more source
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong +8 more
wiley +1 more source
Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity
This study demonstrates that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to produce antitumor neutrophils with enhanced MHC I–mediated CD8+ T cell activation, thereby sensitizing tumors to α‐PD1 therapy. These findings highlight a strategy to target early hematopoiesis for shaping neutrophil fate and potentiating cancer immunotherapy.
Jinsong Tao +11 more
wiley +1 more source
Transcriptomic and Neuroimaging Decoding of Brain‐Immune Crosstalk in Thyroid Eye Disease
This study employed an imaging transcriptomics framework integrating resting‐state fMRI with Allen Human Brain Atlas transcriptomic data, coupled with peripheral blood RNA sequencing, to decode brain‐immune crosstalk in thyroid eye disease. Frontal, parietal, subcortical, and brainstem regions were identified as key neuroimmune‐ vulnerable regions ...
Haiyang Zhang +15 more
wiley +1 more source
Sepsis‐associated encephalopathy (SAE) lacks effective therapies. We developed ME@FDsi, a biomimetic nanodrug using a tetrahedral framework nucleic acid to deliver disulfiram and siTNFα. It crosses the blood‐brain barrier, targets M1 microglia, inhibits pyroptosis and inflammation, and scavenges ROS.
Huimin Shi +15 more
wiley +1 more source

